http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 06:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html si-local-file:///var/storage/secattach/20260612/26637765.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html Fri, 12 Jun 2026 06:01:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html si-local-file:///var/storage/secattach/20260612/26637765.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html Fri, 12 Jun 2026 06:01:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html si-local-file:///var/storage/secattach/20260612/26637765.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+11/26637765.html Fri, 12 Jun 2026 06:01:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html si-local-file:///var/storage/secattach/20260610/26630079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html Wed, 10 Jun 2026 16:16:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html si-local-file:///var/storage/secattach/20260610/26630079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html Wed, 10 Jun 2026 16:16:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html si-local-file:///var/storage/secattach/20260610/26630079.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+10/26630079.html Wed, 10 Jun 2026 16:16:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/26626522.html <p>B.Riley analyst Mayank Mamtani initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $45.00.</p><p>The analyst comments "We are initiating coverage of Ascentage Pharma Group International (AAPG) with a Buy rating and $45 PT. AAPG is a revenue-stage hematology-oncology company with two products approved by in China. Lisaftoclax is a selective BCL-2 inhibitor approved in July 2025 for relapsed/refractory CLL/SLL. Olverembatinib is a thirdgeneration BCR-ABL kinase inhibitor for patients who have stopped responding to earlier kinase inhibitors, specifically in CML. Both drugs anchor a global registrational program of seven FDA-cleared Ph3 trials run http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/26626522.html Wed, 10 Jun 2026 07:17:59 -0400 AAPG http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/26626522.html <p>B.Riley analyst Mayank Mamtani initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $45.00.</p><p>The analyst comments "We are initiating coverage of Ascentage Pharma Group International (AAPG) with a Buy rating and $45 PT. AAPG is a revenue-stage hematology-oncology company with two products approved by in China. Lisaftoclax is a selective BCL-2 inhibitor approved in July 2025 for relapsed/refractory CLL/SLL. Olverembatinib is a thirdgeneration BCR-ABL kinase inhibitor for patients who have stopped responding to earlier kinase inhibitors, specifically in CML. Both drugs anchor a global registrational program of seven FDA-cleared Ph3 trials run http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Ascentage+Pharma+Group++%28AAPG%29+at+Buy/26626522.html Wed, 10 Jun 2026 07:17:59 -0400 AAPG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html si-local-file:///var/storage/secattach/20260601/26579492.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html Mon, 01 Jun 2026 08:00:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html si-local-file:///var/storage/secattach/20260601/26579492.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html Mon, 01 Jun 2026 08:00:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html si-local-file:///var/storage/secattach/20260601/26579492.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Jun+01/26579492.html Mon, 01 Jun 2026 08:00:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html <p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p> <p align="justify">The ASCO Annual Meeting http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Presents+Updated+Clinical+Data+for+Olverembatinib+as+Second-Line+Therapy+in+CML-CP+at+ASCO+2026/26577510.html Sun, 31 May 2026 19:30:00 -0400 36X 6855 A.06822034 A.21266042 A.31066700 A.50216726 AAPG O.20026344 O.21612337 O.22422661 O.22928446 O.38659577